Status:
COMPLETED
Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults
Lead Sponsor:
Stanford University
Conditions:
Obesity
Metabolic Syndrome
Eligibility:
All Genders
40-75 years
Phase:
PHASE4
Brief Summary
The purpose of the study was to determine the effects of growth hormone and an insulin sensitizer drug in pre-diabetic adults with excessive amounts of abdominal fat. Participants received a combinati...
Detailed Description
Treatment with recombinant human growth hormone (GH) has been shown to reduce visceral adipose tissue (VAT) and improve insulin sensitivity in normoglycemic adults, but glucose levels may rise transie...
Eligibility Criteria
Inclusion
- Age between 40 and 75 years
- BMI \> 27 kg/m2
- Waist circumference \>100 cm for men and \> 88 cm for women
- Impaired glucose tolerance (documented by a 75 gram OGTT)
Exclusion
- Diabetes mellitus
- Malignancy
- Premenopausal women who are breastfeeding or decline contraception
- Congestive heart failure
- ALT \> 3 times upper normal limit
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
End Date :
April 1 2005
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00352287
Start Date
March 1 2003
End Date
April 1 2005
Last Update
July 14 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Veterans Affairs Palo Alto Health Care System
Palo Alto, California, United States, 94304